Interim Report Q3 - January - September, 2026 Redsense Medical AB (publ.)
July - September 2026
- Net sales amounted to kSEK 7,630 (6,935).
- Operating result, EBIT amounted to kSEK 1,268 (-428).
- EBIT excl. exchange rate differences kSEK 1,046 (-226).
- Result after tax amounted to kSEK 1,329 (-345).
- Earnings per share were SEK 0.08 (-0.02).
- Exchange rate differences kSEK 222 (-202).
(Other operating income/loss)
Message from the CEO
Consistency providing a stronger foundation for growth
The third quarter marks our third consecutive quarter with a positive operating result and year-on-year revenue growth. Net sales increased to kSEK 7,630 (6,935), with an operating result of kSEK 1,268 (-428). For the first nine months, net sales reached kSEK 21,121 (17,988) and the operating result improved to kSEK 2,722 (-5,414). Together with a cash position exceeding SEK 12 million at the end of September, this demonstrates the more stable operational and financial foundation we have worked to establish.
Underlying demand also continues to develop positively. In the U.S., alarm sales from our distribution partners to end customers increased by approximately 2 percent, while sensor patch sales grew by 12 percent compared with the same quarter last year. This continues the trend of increasing disposable usage alongside relatively stable alarm sales, indicating that our systems are being used more actively.
We continue to work closely with our largest U.S. providers, where discussions around broader implementation and increased usage are progressing. The revised pricing structure, together with our educational support and closer engagement with clinical and procurement teams, remains central to addressing barriers to wider adoption.
Broadening our commercial reach
During the quarter, we participated in several industry meetings and conferences in the U.S. and Europe, with an increased emphasis on nursing-focused events. As more of these meetings have returned following the pandemic, we have been able to reconnect with an audience that has historically been particularly relevant for Redsense. Nurses are the primary users of our technology, and these meetings provide valuable opportunities for product demonstrations, practical feedback and building relationships with clinical decision-makers.
We also returned to the European renal nursing conference, EDTNA, where we presented the Redsense Clamp alongside our established alarm system. For healthcare professionals already familiar with Redsense, the expanded offering generated renewed interest and valuable discussions. While these interactions do not necessarily translate directly into sales, they help maintain awareness and support our ongoing commercial work. Our distribution partners also represented Redsense at national industry meetings in the UK and Canada, while we continued our engagement with providers at the German national nephrology meeting.
Commercial progress for the Clamp continues, although decision processes at larger organisations are taking longer than anticipated. We have recorded smaller sales and received positive feedback from clinical evaluations in both the UK and Germany. Discussions regarding pricing and wider implementation remain ongoing with several larger providers. Our priority is to convert these opportunities into more substantial and repeatable business, while maintaining a disciplined approach to our commercial resources.
Our digital training portal is also gaining users, with more healthcare professionals accessing the platform and providing encouraging initial feedback. We continue to develop the solution to support consistent implementation and make training more accessible across clinics and provider organisations.
Regulatory progress and market opportunities
For the Redsense Clamp in the U.S., we have submitted a request for a follow-up FDA pre-submission meeting. More than three years have passed since our previous dialogue, during which both our product development and regulatory expectations have evolved. We believe renewed engagement is the most efficient way to review our progress, clarify current requirements and evaluate the most appropriate regulatory pathway before proceeding with a formal submission. We will communicate further developments as the process progresses.
Following the quarter, the U.S. Department of Health and Human Services published a new national kidney care plan, reinforcing the focus on home dialysis, patient safety and innovation in kidney care. We view this as a positive development for the market in which Redsense is already established, particularly in home and nocturnal dialysis. We are exploring whether the renewed policy focus may also create opportunities for further engagement around broader adoption, while recognising that reimbursement pathways remain challenging.
Outlook
The first nine months of 2026 demonstrate that the improvements implemented during 2025 are translating into more consistent performance. With three consecutive positive quarters, growing disposable usage and a stronger financial position, we have established a solid foundation from which to develop the business further.
Our focus remains on increasing usage within our existing U.S. customer base, expanding into additional clinics and patient groups, and converting ongoing Clamp opportunities in Europe into larger commercial agreements. We remain encouraged by the interest and feedback from customers, while recognising that implementation decisions within larger healthcare organisations require time.
We will continue to balance commercial ambition with financial discipline, building a business capable of supporting sustainable growth and reaching more patients with improved safety in dialysis care. I would also like to thank the entire Redsense team for their dedication and hard work. The progress we are seeing is the result of a collective effort, and I am proud of what we are achieving together.
Sebastien Bollue
CEO of Redsense Medical
This information is information that Redsense Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. The information was submitted for publication, through the agency of the contact person specified below, on November 18, 2026, at 08:30 CET.